REGISTER HERE

How can AI foundation models shorten the cell therapy developments from discovery to human trials?
What role can AI play in reducing cost per dose? Will it help make therapies accessible beyond rare diseases?
How will pharma and AI-native companies collaborate most effectively in the next five years?
 
Join Ajinomoto Group Ventures, Astellas Venture Management, Avant Bio, and Somite AI on November 12 in Boston for a deep dive into AI investing in the cell therapy sector. Enjoy an afternoon connecting with fellow investors and startups over delicious bites and drinks.

AGENDA

4:00PM: Registration and networking

4:30PM: Program Begins

5:15PM: Networking

6PM: Event Conclusion

Panelists

Nagisa Sakurai, PhD  Investment Lead at Astellas Venture Management

Micha Breakstone, PhD
CEO of Somite AI

Sebastien Latapie 
Partner at Avant Bio

Max von Poelnitz
Managing Director at Ajinomoto Group Ventures